Identification of Dual Super-Response in Patients With Asthma and CRSwNP Treated With Mepolizumab
This study provides new insights into transcriptomic changes following mepolizumab treatment and highlights RGS1 as a potential biomarker for predicting dual super-response in asthma and CRSwNP. Our findings contribute to precision medicine approaches and support the identification of optimal candidates for anti-IL-5 therapy.
Authors
- Catalina Sanz (ORCID: https://orcid.org/0000-0003-2974-0873)
- Jaqueline Perez-Pazos
- Elena Curto (ORCID: https://orcid.org/0000-0002-7291-0543)
- Cristina Martín (ORCID: https://orcid.org/0000-0003-3458-3593)
- Asunción Garcı́a-Sánchez (ORCID: https://orcid.org/0000-0002-9655-4918)
- María Gil‐Melcón
- Miguel Estravís (ORCID: https://orcid.org/0000-0001-9788-4540)
- Juan Carlos Triviño
- María Isidoro‐García (ORCID: https://orcid.org/0000-0002-9013-9422)
- Ignacio J. Davila (ORCID: https://orcid.org/0000-0001-8485-5513)
- Emma Moreno‐Jimenez (ORCID: https://orcid.org/0000-0003-1819-3077)
- Francisco J. Muñoz‐Bellido (ORCID: https://orcid.org/0000-0003-4071-9928)
- M Gómez-García
- Jacinto Ramos
- N. Morgado
- D Carreiras-Quintas
Institutions
- Universidad de Salamanca (ES)
- Instituto de Salud Carlos III (ES)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Complejo Hospitalario de Salamanca (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (ES)
- Instituto de Investigación Biomédica de Salamanca (ES)
- Sistemas Genómicos (ES)
- Instituto de Investigación de Enfermedades Raras (ES)
Publication Details
- Journal
- Journal of Investigational Allergology and Clinical Immunology
- Published
- 2025-12-15
- DOI
- https://doi.org/10.18176/jiaci.1102
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.16